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     INTRODUCTION 
  Invasive pneumococcal disease (IPD) is a major cause of 
morbidity and mortality with an estimated 1.6 million per-
sons dying of pneumococcal disease each year, of which 0.7–1 
million are children less than five years of age living in the 
developing world.  1   The introduction of a seven-valent polysac-
charide-protein conjugate vaccine (PCV-7, Prevnar™; Wyeth 
Lederle Vaccines, Pfizer, New York, NY) has led to a reduction 
in the rate of IPD in the United States and other developed 
countries.  2,  3   Less data on vaccine efficacy are available outside 
western developed nations, although studies in the Gambia 
and South Africa have reported that multi-valent pneumo-
coccal vaccines are safe and effective.  4,  5   The World Health 
Organization has recommended the inclusion of pneumococ-
cal conjugate vaccine in national childhood immunization pro-
grams, particularly in countries where mortality rates among 
children less than five years of age are > 50/1,000 live births or 
where > 50,000 children die annually.  1  
 Major initiatives are currently underway to introduce PCV-7 
and to evaluate the efficacy of vaccination throughout the 
developing world.  6–  8   Serotypes included in PCV-7 (4, 6B, 9V, 
14, 18C, 19F, and 23F) are reported to cover 60–90% of sero-
types associated with IPD in young children in the developed 
world, although the prevalence of serotypes show geographic 
variability and coverage is suggested to be lower in many 
developing countries, such as those in Asia (45%).  9,  10   Other 
pneumococcal vaccines recently available in several coun-
tries include a 10-valent vaccine (PCV-7 serotypes plus sero-
types 1, 5 and 7F; Synflorix™; GlaxoSmithKline, Brentford, 
United Kingdom), and a 13-valent vaccine (PCV-10 serotypes 
plus serotypes 3, 6A and 19A, Prevnar 13®; Wyeth Lederle 
Vaccines). 
  The incidence of IPD, circulating serotypes, and predicted 
vaccine efficacy in resource-poor Asia are poorly defined. 
Only a single, large-scale vaccine efficacy study has been con-
ducted in the Philippines.  8   In Laos, mortality in children less 
than five years of age was 70/1,000 in 2007. Immunization rates 
during the same year were low as reflected by a measles vac-
cination rate of 40%,  11   and pneumococcal vaccination is not 
currently a component of the national program. Laos is one of 
several developing countries in Southeast Asia that has almost 
no or limited data on the burden of pneumococcal disease. 
A large study of the causes of community-acquired bacteremia 
at Mahosot Hospital, Vientiane (the capital of Laos), which 
included 4,512 blood culture pairs from adults and children 
during 2000–2004, provided the first data on   S. pneumoniae  
for this country.  12   The frequency of detected   S. pneumoniae  
bacteremia was surprisingly low in children (2.1% of blood 
culture positive children) and adults (1.2% of positive adults). 
The serotypes responsible and outcome from invasive pneu-
mococcal disease in Laos have not been reported. 
  We describe the burden of IPD among patients who pro-
vided blood and/or cerebrospinal fluid (CSF) for culture after 
admission to Mahosot Hospital over a period of six years and 
the serotypes of infecting pneumococci. The addition of a 
real-time polymerase chain reaction (PCR) for detection of 
  S. pneumoniae   in CSF led to a doubling in numbers of pneu-
mococcal meningitis detected. To provide a more complete 
picture of circulating serotypes, we developed a real-time PCR 
serotyping method that encompassed the serotypes present in 
the 13-valent vaccine. 
   MATERIALS AND  METHODS 
  Study  site.     A prospective study was conducted during 
January 2003–April 2009 at Mahosot Hospital, Vientiane, 
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a 365-bed hospital with approximately 1,200 admissions 
per month. The study of IPD reported was part of a larger 
evaluation of all-cause sepsis and/or meningitis conducted 
over the same period. Ethical approval was granted by the 
Ethical Review Committee of the Faculty of Medical Sciences, 
National University of Laos and the University of Oxford 
Tropical Ethics Research Committee. 
      Patient recruitment, sampling, and case definitions.    Patients 
were recruited after giving informed verbal consent for blood 
cultures (written informed consent from 2007) if community-
acquired septicemia was suspected, and after informed written 
consent for lumbar puncture removal of CSF (parents or 
guardians were asked to determine consent for children) if 
meningitis was suspected. Recruitment was at the discretion 
of the responsible physician. History and clinical examination 
were recorded on a standard form. Two blood cultures were 
taken from each patient, as described.  12   The volume of blood 
taken for culture was 5 mL/bottle for adults (≥ 15 years of 
age), 2 mL/bottle for children > 1 year of age, and 1 mL/bottle 
for infants. The blood culture bottles used varied according to 
patient age: bottles containing 50 mL of broth were used for 
adults, 20 mL for children, and 10 mL for infants. Immediately 
after lumbar puncture, 2–3 drops of CSF were placed onto a 
goat blood agar plate and a chocolate agar plate. 
  A case of IPD was defined as a patient who had a positive 
culture for   S. pneumoniae   in blood and/or CSF, and/or had a 
positive result for   S. pneumoniae   in CSF by a real-time PCR 
assay specific for   lytA . 13   Meningitis was defined as detection 
of   S. pneumoniae   in the CSF or in blood from a patient with 
a clinical syndrome consistent with meningitis.  1   Patients with 
  S. pneumoniae   isolated from blood who had CSF that was neg-
ative for   S. pneumoniae   or did not have CSF taken and had 
no evidence for pneumococcal meningitis were categorized as 
having bacteremia. Death was recorded up to the time of hos-
pital discharge. 
      Microbiologic culture and bacterial identification.    Blood 
culture bottles were processed as described.  12   The  CSF 
samples and plates were transported immediately from the 
ward to the diagnostic laboratory. A cell count was performed 
on CSF by using a standard method.  14   A total of 500 μL of CSF 
was centrifuged at 13,000 rpm for 5 minutes, the supernatant 
removed, and the material examined after Gram staining. 
The remaining pellet was divided between a goat blood agar 
plate, a chocolate agar plate, and tryptone soya broth, which 
was subcultured onto blood agar and chocolate agar after 
incubation at 37°C in an atmosphere of 10% CO  2   for 24 hours. 
All agar plates were incubated at 37°C in an atmosphere of 10% 
CO  2   for 72 hours and visually inspected daily.   Streptococcus 
pneumoniae   was identified by using standard microbiologic 
methods, which included colony morphology, Gram stain, 
optochin susceptibility, and bile solubility. All isolates were 
stored at –80°C in Protect™ Bacterial Preservation Cryovials 
(Fisher Scientific, UK). The serotypes of clinical  S. pneumoniae  
isolates cultured at Mahosot Hospital were determined by 
using the Quellung reaction,  15   which was performed at the 
John Radcliffe Hospital, Oxford, United Kingdom. 
   Antimicrobial  drug  susceptibility  testing.    Susceptibility  to 
penicillin (minimum inhibitory concentration) was determined 
by using the Etest (AB Biodisk, Solna, Sweden), as described 
by the Clinical and Laboratory Standards Institute.  16   The 
revised penicillin breakpoints (for intravenous administration) 
introduced in 2008 were used to define susceptibility of isolates 
associated with infections other than meningitis (susceptible, 
≤ 2 μg/mL; intermediate, 4 μg/mL; and resistant, ≥ 8 μg/mL) 
and for isolates associated with meningitis (susceptible, ≤ 0.06 
μg/mL; intermediate, none; and resistant, ≥ 0.12 μg/mL).  17  
Susceptibility to ceftriaxone, chloramphenicol, ofloxacin, and 
trimethoprim/sulfamethoxazole were also defined by Etests 
according to Clinical and Laboratory Standards Institute 
breakpoints.  16   Susceptibility to erythromycin was determined 
by using the disk diffusion method,  16   with intermediate and 
resistant isolates being grouped as nonsusceptible. If blood 
and CSF cultures were positive for   S. pneumoniae  , results for 
the isolate from CSF were presented. 
   Laboratory  isolates.     Three isolate collections were used 
during the development and validation of the real-time 
PCR serotyping assay. These were 1) a panel of reference 
  S. pneumoniae   isolates of known serotype (  Table 1  ); 2) a 
collection of 121 additional  S. pneumoniae  isolates representing 
13 vaccine serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 
and 23F) and 35 isolates representing an additional 8 serotypes, 
which are either relatively common or belong to the same 
serogroup as found in PCV-13 (7B, 7C, 8, 9N, 19C, 23A, 23B, 
and 24A); and 3) a collection of non-pneumococcal isolates, 
with 1 isolate of each of the following species:   Enterococcus 
faecalis ,   E. faecium ,   Streptococcus bovis ,   S. mitis ,   Listeria 
monocytogenes ,   Haemophilus influenzae ,   H. parainfluenzae , 
  Enterobacter cloacae ,   Shigella sonnei ,   Citrobacter freundii , 
  Klebsiella pneumoniae  , and   Proteus mirabilis   (all obtained 
from the United Kingdom National External Quality 
Assessment Service scheme),   Staphylococcus aureus   ATCC 
25923,   S. epidermidis   NCTC 11047,   S. viridans   NCTC 10712, 
  Neisseria meningitidis   NCTC 10025,   Esherichia coli   ATCC 
25922, and   Pseudomonas aeruginosa  ATCC 27853. Additional 
species were included to represent pathogens that may cause 
central nervous system infection in Southeast Asia. These 
species were one clinical isolate each of   Streptococcus suis   and 
  Leptospira interrogans   serovar Autumnalis, and the reference 
strains   Orientia tsutsugamushi   strain Gilliam and   Rickettsia 
typhi   strain Wilmington (kindly provided by the Australian 
Rickettsial Reference Laboratory, Geelong, Victoria, 
Australia). 
 Table 1 
   Streptococcus pneumoniae   reference isolates used in the study, Laos   
Source Strain no.
  S. pneumoniae  
serotype
Health Protection Agency Culture 
Collection, London, United Kingdom
NCTC 7465 1
NCTC 7978 3
NCTC 11886 4
NCTC 11887 5
NCTC 11888 6B
NCTC 11890 7A
NCTC 11889 7F
NCTC 11894 9A
NCTC 11895 9L
NCTC 11896 9N
NCTC 11897 9V
NCTC 11902 14
NCTC 11905 18C
NCTC 11907 19A
NCTC 12977 19F
NCTC 11910 23F
Statens Serum Institut, Copenahgen, 
Denmark
SSISP 18A/2
SSISO 18B/2
18A
18B
SSISP 18F/1 18F453 REAL-TIME PCR TO DEFINE PNEUMOCOCCAL SEROTYPE
       DNA  extraction  from  bacteria  and  CSF.    DNA  was 
extracted from bacterial isolates by using the High Pure PCR 
Template Preparation Kit (Roche, Welwyn Garden City, UK) 
according to the manufacturer’s protocol and the addition of 
mutanolysin (5 μL at a concentration of 10 mg/mL), lysostaphin 
(5 μL at a concentration of 10 mg/mL), and lysozyme (5 μL at 
a concentration of 10 mg/mL) (Sigma, St. Louis, MO) as appro-
priate at the cell lysis stage to promote lysis of   S. pneumoniae , 
  S. aureus  , and coagulase-negative staphylococci. DNA was sus-
pended in a final volume of 200 μL of buffer. DNA extraction 
from 200 μL of CSF was performed by using the QIAGEN 
DNA Mini protocol (Qiagen, Valencia, CA),  18   with the modi-
fication that lysozyme (5 μL at a concentration of 10 mg/mL) 
and mutanolysin (5 μL at a concentration of 10 mg/mL) 
(Sigma) were added during a 30-minute lysis step at 37°C. 
DNA was eluted in 80 μL of Qiagen elution buffer. 
      Real-time PCR to detect   S. pneumoniae   in CSF.    All  CSF 
samples were tested for   S. pneumoniae   by using a real-time 
PCR specific for   lytA  , primers and probe described,  13   and 
conditions described below. 
      Development of molecular capsular typing by using real-
time PCR.    Primer and probe design and multiplex PCR scheme.  
  Twelve primer pairs and fluorescent dye-labeled probes were 
designed to target the serotypes present in the 13-valent 
vaccine (serotypes 1, 3, 4, 5, 6A/B, 7F, 9V, 14, 18C, 19A, 19F, and 
23F) (a single serotype 6 assay would be predicted to amplify 
6A/B/C). The relevant   cps   gene sequences for each serotype 
were downloaded from the National Center for Biotechnology 
Information (Bethesda, MD) website (  http://www.ncbi.nlm
.nih.gov/  ) and aligned. Differences between serotypes within 
the same serogroup were highlighted and primers and locked 
nucleic acid probes for use in Taqman PCRs were selected 
and synthesized by Sigma Aldrich (Dorset, United Kingdom). 
Serotype-specific genes selected from the   cps   locus were 
  wchD   (serotype 1),   wchE   (serotype 3),   wzy   (serotype 4), 
  whaC-whaD   (serotype 5),   wzy-wzx   (6A/B/C),   aliB   (7A/F), 
  cps9vJ   (9A/V),   wzy   (14),   gct   (18B/C),   mnaA   (19A),   wzy   (19F), 
and   wzy-wchV   (23F). 
  Each primer pair and probe were compared with all 
  cps   sequences using the basic local alignment search tool 
(BLAST) website (  http://blast.ncbi.nlm.nih.gov/Blast.cgi  ) 
and BLAST search on the Sanger website (  http://www.sanger
.ac.uk/Projects/S_pneumoniae/CPS/  ) to determine specificity. 
The probes were labeled at the 5′ end with either 6-carboxy-
fluorescein (FAM; serotypes 3, 7A/F and 19F), hexachloro-6-
6-carboxyfluorescein (HEX; serotypes 1, 6A/B/C, 18B/C and 
19A), cyanine (Cy5; serotypes 4, 9A/V, and 23F), or 6-carboxy-
X-rhodamine (ROX; serotype 5 and 14). Black hole quencher 
(BHQ; Sigma) was attached at the 3′ end of each probe (either 
BHQ1 or 2, depending on the probe dye). Primer and probe 
sequences are shown in   Table 2  . Primers and probes were 
grouped into three multiplex reactions and one single target 
reaction. Multiplex 1 was designed to amplify serotypes 1, 3, 
4, and 5, multiplex 2 to amplify 6A/B/C, 7A/F, 9A/V, and 14, 
 Table 2 
    Primers and probes used in the study, Laos  *     
Serotype Accession no. Primer/probe Sequence (5′→3′) Primer position at   cps   locus Product size, basepairs
1 CR826497.1 For CTATAGAAGGTCTACATCAGGTTC 8626–8784 159
Rev TTTCTGTCAGATACGGCTTAC
Probe HEX-TCT+TCA+ATG+CGT+AGT+CTGC-BHQ1
3 Z47210.1 For ATGTTATTACACTCCTGTTCCTG 7282–7413 132
Rev TCTAGGCGTCCATACTGTATC
Probe FAM-AGA+ACT+GTA+ATA+TCA+CTCTGCGA-BHQ1
4 AF316639.1 For TATTTCTAGGGTAATAACTGATTCTAAAAC 9990–10099 110
Rev CTCCTAAATCATCTATTATTCCTGAAC
Probe Cy5-CTG+CCT+CTG+AAT+ATG+CTGAAT-BHQ2
5 CR931637.1 For TCCGAACGAAGATATTTGGTG 9143–9252 110
Rev ATATAGAATTCCCCTCATGAACAC
Probe ROX-ACC+ACA+ACA+TCC+TCA+ATCAAC-BHQ2
6A/B/C CR931638.1 For TATTATTCTTTAGGGAATGTGTATACTG 10290–10391 102
Rev ATATAACCACGCTGTAAAACTC
Probe HEX-CAA+TAC+CAA+TTA+CAC+CAAAGTCT-BHQ1
7A/F CR931643.1 For CCTTATAAATTTTGTGACTATAGACCTG 9799–9902 104
Rev CCTAGTAAGACATCTGTGTCAC
Probe FAM-AAC+CCC+AGT+AAT+CAT+AACCC-BHQ1
9A/V CR931648.1 For GTTAGTTGCTTCTTACAGGAAATAC 10014–11411 115
Rev AAATTCATATTCCCACTCATTGTATG
Probe Cy5-ACT+TCC+ATC+AGT+AAG+CAGTTT-BHQ2
14 CR931662.1 For TCTATATACAAAGAGGCTCCAATG 7492–7592 101
Rev ACCTGTATATCTTACACCATAACTAG
Probe ROX-AAA+TCC+GTC+CCA+GTC+TAAC-BHQ2
18B/C CR931673.1 For TCGATTTAGTAATCCCTGAAAC 15812–15922 111
Rev GATAATCAAATTTACCTTTCCAATC
Probe HEX-TCA+GAT+GTT+AAA+GACTACC-BHQ1
19A CR931675.1 For AGAGGATTATACACACACTCATTTAG 12650–12730 81
Rev AGATTTTCGCGTCTATGAGC
Probe HEX-CGC+TAA+CAA+TCG+TCT+CATCTT-BHQ1
19F CR931678.1 For TCGGACACTAGGAGTTACTG 11848–11955 108
Rev AAAGCACCTACAGCAAAGAC
Probe FAM-ACA+TAC+ATA+CCA+ACT+AGA+CCAA-BHQ1
23F CR931685.1 For GAACGGTAGAGATGCCTTTAC 9273–9366 94
Rev GAAGATATAAACTTAAACAGCACTATAATG
Probe Cy5-CAA+CTA+ACC+CAA+CAT+AAC+CATTT-BHQ2
    *     For = forward; Rev = reverse.   454 MOORE AND OTHERS
multiplex 3 to amplify 18B/C, 19F, and 23F, and the single tar-
get reaction for serotype 19A. 
        Real-time  PCRs.     All PCRs were optimized for the Corbett 
Rotor-Gene 6000 series (Corbett Life Science, Sydney, New 
South Wales, Australia) in a 25-μL reaction containing 1× PCR 
buffer, 5.5 mM MgCl  2 ,  200  μM of each dNTP, variable primer 
and probe concentration (see below), 1 unit of AmpliTaq Gold 
DNA polymerase, and 3 μL of DNA extract from CSF samples 
or 2 μL of extracted bacterial DNA. After optimization, the 
primer and probe concentrations used were as follows: each 
primer,   lytA  , 300 nM; capsular multiplex reactions 1 and 2, 
240 nM; multiplex reaction 3 and single target reaction, 300 
nM; each probe:   lytA  , 100 nM; multiplex 1 and 2, 40 nM of 
FAM-labeled probes (serotypes 3 and 7A/F) and 80 nM each 
of probes labeled with other dyes (serotypes 1, 4, 5, 6A/B/C, 
9A/V, and 14); multiplex 3, 50 nM of FAM-labeled probe 
(serotype 19F) and 100 nM each of probes labeled with other 
dyes (serotypes 18B/C and 23F); and single reaction, 100 
nM of probe (serotype 19A). DNA was amplified by using 
45 cycles at 95°C for 15 seconds and 60°C for 60 seconds.  19  
Amplification data were analyzed by using Rotorgene 6000 
software version 1.7 (Corbett Life Science). The relevant 
positive control (2 μL of genomic DNA) and negative control 
(reaction mixture minus template) were included in each run. 
Positive samples were defined as those with a cycle threshold 
(C  T )  < 40. The lower limit of detection was determined by 
using serial 10-fold dilutions of purified DNA from known 
pneumococcal serotypes. 
     RESULTS 
  Detection  of   S. pneumoniae   in blood and CSF.    Blood 
cultures were obtained from 10,799 patients during January 
2003–April 2009 for the investigation of suspected bacte-
rial sepsis, of which 23 (0.21%) were culture positive for 
  S. pneumoniae  . A total of 353 patients had a CSF sample taken 
for investigation of suspected meningitis, of which 19 (5.4%) 
were defined as having pneumococcal meningitis on the basis 
of culture and positive  lytA  PCR results (n = 9), or positive  lytA  
PCR results alone (n = 10). Seven patients were positive for 
  S. pneumoniae   in blood culture and CSF samples, 12 patients 
had a positive CSF result and a negative blood culture, and 
16 patients had a positive blood culture alone. Therefore, we 
describe 35 patients with IPD. Features in patients with positive 
blood cultures alone were no known focus of infection (n = 8), 
pneumonia (n = 7), and clinical meningitis with no CSF sample 
taken (n = 1). 
  The median age of the 35 patients with IPD was 17 years 
(range = 1 month to 82 years, interquartile range = 1.5–34.8 
years); 11 (31%) patients were less than five years of age. 
The crude in-hospital mortality rate was 31% (11 of 35). Of 
those who died, five patients had bacteremic meningitis, two 
had meningitis, and four had bacteremia alone. The median 
age in patients who died was 20 years (range < 1–63 years). 
   Antimicrobial  drug  susceptibility.     Susceptibility testing was 
completed for isolates from 23 of the 35 patients. This testing 
could not be completed for 12 patients because the diagnosis 
was based on a positive  lytA  PCR result only for CSF (n = 10) or 
because isolates could not be recovered from frozen stocks (n = 2). 
Two isolates associated with meningitis were not susceptible 
to penicillin (minimum inhibitory concentrations = 0.39 μg/
mL and 0.125 μg/mL, respectively). All 23   S. pneumoniae   were 
susceptible to ceftriaxone and ofloxacin. Resistance patterns 
to other antimicrobial agents were erythromycin, 3 isolates 
(13%); chloramphenicol, 3 isolates (13%); and trimethoprim-
sulfamethoxazole 14 isolates (61%). Seven isolates (30%) were 
fully susceptible to all antimicrobial drugs tested, six isolates 
(26%) were resistant to one antibiotic, six isolates (26%) 
were resistant to two antibiotics, and four isolates (17%) were 
resistant to ≥ 3 of the antimicrobial agents tested. 
      Sensitivity and specificity of real-time PCR serotype 
assay.     The lower limit of detection was defined for the 12 
serotype-specific PCR assays by using serial 10-fold dilutions 
of purified DNA extracted from the relevant control strains 
for each pneumococcal serotype. The lower limit of detection 
in the multiplex reactions ranged from 0.35 to 26.4 genomic 
equivalents per reaction. Verification of assay specificity was 
performed by using genomic DNA from a range of other 
bacterial species. No amplification products were detected in 
the three multiplex or one single target reactions for any of 
the non-pneumococcal species tested, which indicated 100% 
assay specificity for   S. pneumoniae  . Specificity of the PCR 
primers for specific serotypes was assessed by using the panel 
of reference isolates of known serotypes (  Table 1  ). Primers 
were shown to be serotype specific with no cross-reactions 
between serotypes. 
      Validation and application of pneumococcal serotyping by 
using real-time PCR.     A blinded evaluation was performed 
in which serotype determined by the Quellung reaction 
and the PCR were compared for 121   S. pneumoniae   isolates 
with serotypes represented in the PCV-13 vaccine (  Table 3  ). 
There was 100% concordance between these two assays. An 
additional 35 isolates representing other serotypes as defined 
by the Quellung reaction that are not in the PCV-13 vaccine 
but that have been reported to cause IPD worldwide or 
are closely related to the vaccine serotype were negative by 
the PCR. 
  The 10 CSF samples that were culture negative but positive 
by   lytA   PCR were evaluated by real-time PCR to determine 
the serotype of the infecting isolate. The serotypes were type 1 
(n = 2), 5 (n = 2), 6A/B/C (n = 1), and undetermined (no prod-
uct) (n = 5). These data enabled us to define the serotype of 
 Table 3 
    Concordance between serotype as defined by the Quellung reaction 
and real-time PCR assay for 121 laboratory isolates of  Streptococcus 
pneumoniae ,  Laos *   
Serotype by Quellung reaction Serotype by real-time PCR No. isolates tested
11 7
33 9
44 8
55 8
6A/B/C †  6A/B/C 23
7A/F †  7A/F 12
9A/V †  9A/V 13
14 14 9
18B/C †  18B/C 6
19A 19A 9
19F 19F 8
23F 23F 9
Total 121
  *   PCR = polymerase chain reaction. Results are shown for serotypes present in the 13-valent 
polysaccharide-protein conjugate vaccine. Concordance was 100% for all serotypes tested.   
    †      These results include the following Quellung results: 6A, n = 9; 6B, n = 9; 6C, n = 5; 7A, 
n = 3; 7F, n = 9; 9A, n = 4, 9V, n = 9; 18B, n = 1; and 18C, n = 5. An additional 35 strains rep-
resenting additional Quellung-defined serotypes not present in this vaccine (7B, n = 3; 7C, 
n = 6; 8, n = 2; 9N, n = 8; 23A, n = 9; 23B, n = 6; and 24A, n = 1) were tested by real-time PCR 
and gave negative results.   455 REAL-TIME PCR TO DEFINE PNEUMOCOCCAL SEROTYPE
28 of 35 patients with IPD (not including the 5 unknowns and 
2 isolates that could not be recovered from frozen stocks). 
Summary data for pneumococcal serotypes as defined by 
Quellung and PCR or PCR alone are shown in   Table 4  . The 
most frequent serotype defined was 1 (n = 6), followed by 
serotypes 5, 6A/B/C, 14, and 23F. 
           Overall,  25  (76%)  of  33  patients  were  infected  with  a  strain 
that was represented in the PCV-13 vaccine, with coverage of 
73% (24 of 33) for the PCV-10 vaccine and 39% (13 of 33) for 
the PCV-7 vaccine. Serotype 6 strains (6A, 6B, and 6C) were 
considered as a single entity for this calculation because they 
were indistinguishable by PCR. If one considers only those 
cases in children less than five years of age (n = 11), cover-
age for PCV-13, PCV-10, and PCV-7 was 73%, 73%, and 45%, 
respectively. Only seven cases were in children less than two 
years of age, four (54%) of whom had IPD caused by a strain 
represented in the PCV-7 vaccine. 
    DISCUSSION 
  This is the first study of IPD in Laos and presents the first 
data on   S. pneumoniae   serotypes of invasive isolates in this 
setting. We found that   S. pneumoniae   was rarely identified as 
a cause of bacterial infection in comparison with studies con-
ducted in Europe and North America.  9,  10  Possible explanations 
for this finding are either that the rate of pneumococcal car-
riage (the forerunner to disease) is low in our setting, or that 
IPD was more common than these culture and/or PCR results 
suggest, with false-negative culture and PCR results leading to 
an underestimation of the true incidence of IPD. Because the 
rate of pneumococcal carriage has not been reported for any 
age group in Laos, the first possibility remains to be tested, 
although children 1–16 years of age living in nearby Vietnam 
have been reported to have a carriage rate of 44%.  20   A  study 
conducted in Thailand reported an annual incidence rate for 
hospitalized pneumococcal bacteremia of 3.7 and 7.6 cases 
per 100,000 persons for two rural provinces, respectively.  21  The 
possibility that our study underestimates the true incidence 
of IPD is highly plausible, especially because of the high fre-
quency of consumption of antimicrobial drugs prior to culture 
in our patient population. A wide range of over-the-counter 
antibiotics are available in Laos, and self-medication is com-
mon during a febrile illness. This finding is supported by recent 
evidence that 56.8% of patients admitted in Mahosot Hospital 
whose investigations included a lumbar puncture had anti-
microbial drug activity detected in their urine (Khennavong 
M, unpublished data). The number of CSF samples that were 
positive for   S. pneumoniae   doubled when examined by using 
PCR, and the application of molecular methods to blood sam-
ples could lead to a further increase in detection of IPD. 
  Although the number of clinical isolates available for test-
ing in this study was low, we found that serotypes 1, 5, 6A/B, 14, 
and 23F were most commonly identified. A study of pneumo-
coccal carriage in children in Vietnam reported that serotypes 
23F, 19F, 6B, and 14 predominated.  22   In Thailand, studies of 
  S. pneumoniae   isolated from patients admitted to hospitals 
have demonstrated some variation in the predominant sero-
types, with 23F, 19F, and 6B predominating in a study con-
ducted in northern regions,  23   serotypes 6, 23, 19, 3, and 11 
predominating in Bangkok,  24   and serotypes 14, 6B, 3, and 19A 
predominating in the northeastern regions.  21   A study (Asian 
Network for Surveillance of Resistant Pathogens) of 996 iso-
lates from 11 countries in Asia demonstrated that serotypes 
23F and 19F predominated, followed by serotypes 6 and 14,  25  
and the same four serotypes were reported to predominate in 
Colombo, Sri Lanka.  26   The five most common serotypes caus-
ing invasive pneumococcal infection in China were reported to 
be 19F, 14, 19A, 6B, and 23F.  27   Thus, our finding that serotype 
1 predominated is different from data for several countries in 
the region, although it is similar to a recent study conducted 
in Nepal where serotype 1 predominated, followed by 5, 2, and 
7F.  28   Serotype 1 is often associated with outbreaks, but patients 
in this study infected by serotype 1 isolates were not related in 
time or place. 
  The small number of isolates we were able to examine will 
necessarily mean that our data have wide error margins, and 
further studies are required with larger numbers of isolates. 
Our finding that PCV-7 vaccine coverage would be predicted 
to be low in Vientiane is a potentially important observation 
for Laos, and further studies are urgently required to confirm 
this finding and determine whether this is the case elsewhere 
in the country. This finding of low vaccine coverage by PCV-7 
is not unique in our region; a rate of 51% has been reported in 
a study in nearby northeastern Thailand.  21   The estimated vac-
cine coverage for Thailand is similar when isolates associated 
with carriage are considered.  29,  30  
  The use of PCR more than doubled the estimated burden 
of   S. pneumoniae   associated with meningitis compared with 
culture alone. Our real-time PCR identified those serotypes 
in the PCV-13 vaccine and gave results that were concor-
dant with those of the Quellung reaction, and without cross-
reactivity with other potential pathogens causing meningitis. 
This assay could be used to define prevalent serotypes prior 
to vaccination programs in settings where patients commonly 
use antimicrobial drugs prior to hospital presentation. Our 
results echo the findings from a study of pneumococcal dis-
ease in children in Vietnam, in which culture was supported 
by antigen detection by using an immunochromatographic 
test and conventional PCR.  31   Culture only confirmed one case 
of   S. pneumoniae  , with an additional 16 children identified as 
having pneumococcal disease on the basis of antigen detec-
tion (n = 12) or PCR (n = 4).  31   Previous studies have used 
 Table 4 
    Serotypes of 33 pneumococcal isolates associated with invasive 
pneumococcal disease in Laos  *     
Serotype † 
Quellung 
reaction and 
PCR (n = 23)
PCR positive 
alone 
(n = 10)
Total 
(n = 33)
Children 
< 5 years 
of age
Associated with 
meningitis/
< 5 years of age
1 4 2 6 1 3/1
4 2 0 2 0 1/0
5 2 2 4 2 2/2
6A/B/C 2 1 3 0 2/0
7F 1 0 1 0 0
9V 1 0 1 0 0
14 3 0 3 3 2/2
18C 1 0 1 0 1/0
19A 1 0 1 0 1/0
23F 3 0 3 2 1/0
15C 1 ‡  0 1 1 0
23B 1 ‡  0 1 0 1/0
38 1 ‡  0 1 0 0
Unknown 0 5 5 2 5/2
  *   PCR  =  polymerase  chain  reaction.  
    †     No serotype 3 or 19F isolates were found in our collection.   
    ‡     Determined by Quellung alone as primers for serotypes 15C, 23B, and 38 are not included 
in real-time PCR assay results.   456 MOORE AND OTHERS
conventional PCR to determine serotype by using   cps   genes 
as targets.  32–  34   However, these studies used numerous multi-
plexes in a single reaction or a number of different multiplex 
reactions and steps to deduce the serotype. Although a real-
time PCR approach uses multiple reactions, the sensitivity is 
higher than that of conventional PCR. The increased sensitiv-
ity of real-time PCR could lead to introduction of the tech-
nique into the clinical setting, especially for samples in which 
bacterial load is low. 
  A limitation of our PCR assay is that some highly related 
serotypes that can be distinguished by the Quellung reaction 
cannot be distinguished by the PCR. For example, 6A, 6B, and 
6C serotypes, although not always easy to distinguish by the 
Quellung reaction,  35   were grouped in our PCR and require a 
detailed scheme to distinguish between them by using a molec-
ular approach.  36,  37   Both 6A and 6B are found in the 13-valent 
pneumococcal vaccine, and an additional probe that can dis-
tinguish 6C may be advantageous because cross-reactivity 
has been reported to occur between 6A and 6B, but not with 
6C.  38   Similar to other assays,  32,  33   our assay also failed to distin-
guish between serotypes 7A and 7F, 9A and 9V, and 18B an 
18C. Those serotypes (7A, 9A, and 18B) not in the PCV-7 vac-
cine are reportedly rare worldwide. There may be some cross-
protection between serogroups found in the vaccine, although 
this has yet to be determined for many of the serotypes.  39   Our 
strain collection did not contain serotypes 7A or 9A as defined 
by Quellung serotyping. 
  Because the incidence of IPD in this study was low and 
coverage using the PCV-7 vaccine would be predicted to be 
relatively low, it is a matter for debate as to whether a pneu-
mococcal vaccine should be a high priority public health inter-
vention in Laos until such times as there is evidence to support 
this suggestion. Further studies are urgently needed to deter-
mine whether these findings are reproducible elsewhere in 
Laos, to determine whether this represents a true picture of 
the burden of IPD or is an underestimate, and to define the 
most appropriate vaccine for the prevention of pneumococcal 
disease in this setting. 
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